Further research is needed using biomarkers in early pregnancy, such as chorionic gonadotropin, metalloproteinases, and HMGB-1 [21,22,23,24,42,43], to assess their potential for predicting women with uterine fibroids who are at higher risk of faster growth and adverse perinatal outcomes. The gene discussed is HMGB1; the disease is uterine corpus leiomyoma.